The primary cutaneous lymphomas are often indolent but difficult to treat. In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking. The purine analog 2-chlorodeoxyadenosine (2CdA) acts in nonHodgkin's lymphoma and has been used in our center for the treatment of advanced primary cutaneous T-cell lyphomas (CTCL). Here, we report on the efficacy and side effects of 2CdA in six patients with CTCL. One patient died owing to myelosuppression. Partial responses were seen in four cases but full remission was observed in only one case. We concluded that 2CdA has a limited usefulness in the management of advanced CTCL.
Introduction
A purine analog 2-chlorodeoxyadenosine (2-CdA) has been accepted as the treatment of choice in hairy cell leukemia and low-grade non-Hodgkin's lymphomas. It has also been recommended in stage IV A/B of cutaneous T-cell lymphomas (CTCL), along with chlorambucil, liposomal doxorubicin, CHOP polychemotherapy, denileukin difitox, and others. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The aim of our study was to analyze the efficacy and side effects of 2CdA treatment for CTCL.
Materials and Methods
We treated six CTCL patients (five with mycosis fungoides; four in stage IIB, one in IVB, and one with peripheral cutaneous T-cell lymphoma (PTCL), unspecified) with 2CdA (pulses of 0.12 mg/kg/day/5 days). 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] The patients failed standard therapies including glucocorticoids, retinoids, methotrexate, radiotherapy, and phototherapy. The efficacy of the treatment was established based on the clinical evaluation of skin lesions and internal involvement.
Results
The patients received 1-8 pulses of 2CdA (Table 1, Figures 1-4) . One patient achieved total remission (patient 46/F, Figure 2A and B), lasting six months. Partial remission was achieved in four cases. Progression of the disease during treatment appeared in one case (patient 71/F, Figure 4 ). One patient died because of myelosupression and staphylococcal sepsis just after the second pulse with 2CdA (patient 43/F, Figure 1 ). We tried to avoid the (Fig. 3A, B (Fig. 4A, B) 1/0.12 mg/kg (7 mg/d) Progressive disease Not applicable Progressive disease
Response: slight, <25%; moderate, 25-50%; significant, 50-75%; total, 100%; PTCL, primary cutaneous peripheral T-cell lymphoma. (Table 2) .
Discussion
2CdA therapy was mostly well tolerated in view of the known side effects (Table 4) although one patient died just after the second pulse because of myelosupression. The observed remissions were short-lasting. Table 3 shows the experience with 2CdA in other centers. 8, 13, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Based on these data, we cannot recommend 2CdA as a routine treatment of CTCL. We concluded that 2CdA is moderately effective in CTCL, giving remission in approximately 67% of patients. The remissions are very short and there is a considerable risk of fatal infections owing to immunosupression.
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